Results 101 to 110 of about 6,942 (191)
Efficacy and safety of dihydroartemisinin–piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial
Malaria Journal, 2019 Background HIV-infected individuals on antiretroviral therapy (ART) require treatment with artemisinin-based combination therapy (ACT) when infected with malaria.Esperança Sevene, Clifford G. Banda, Mavuto Mukaka, Sonia Maculuve, Salésio Macuacua, Anifa Vala, Mireia Piqueras, Linda Kalilani-Phiri, Jane Mallewa, Dianne J. Terlouw, Saye H. Khoo, David G. Lalloo, Victor Mwapasa +12 moredoaj +1 more sourceEffect of food on the pharmacokinetics of piperaquine and dihydroartemisinin
, 2015 BACKGROUND AND OBJECTIVE Piperaquine–dihydroartemisinin combination therapy has established efficacy for the treatment of malaria; however, a more comprehensive understanding of the pharmacokinetic properties and factors contributing to inter- and intra ...Evans, A., Lungershausen, Y., Ubben, D., Reuter, S., Shakib, S., Bacchieri, A., Pace, S., Valentini, G., Francis, B. +8 morecore +1 more sourcePharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria.
, 2011 Dihydroartemisinin-piperaquine is a fixed-dose artemisinin-based combination treatment. Some antimalarials have altered pharmacokinetics in pregnancy. Pregnant women in the 2nd or 3rd trimester and matched nonpregnant women with uncomplicated falciparum ...Phyo, AP, Rose McGready, Nicholas White, Mu, O, Singhasivanon, P, Laochan, N, Than, HH, Oh Mu, Joel Tarning, Aung Phae Phyo, Pratap Singhasivanon, Mcgready, Rose, Natthapon Laochan, Lindegardh, N, Aye Kyi Win, Win, AK, Tarning, J, Rijken, MJ, Marcus J. Rijken, Nosten, F, Niklas Lindegardh, White, N, Hla Hla Than, François Nosten +23 morecore +1 more sourcePost-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana.
PLoS ONE, 2017 BackgroundUncommon and rare adverse events (AEs), with delayed onset may not be detected before new drugs are licensed and deployed. The present study examined the post licensure safety of dihydroartemisinin-piperaquine (DHP) as an additional treatment ...Abraham R Oduro, Seth Owusu-Agyei, Margaret Gyapong, Isaac Osei, Alex Adjei, Abena Yawson, Edward Sobe, Rita Baiden, Martin Adjuik, Fred Binka +9 moredoaj +1 more sourcePopulation pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections
CPT: Pharmacometrics & Systems PharmacologyArtemisinin‐based combination therapy (ACT) is the first‐line recommended treatment for uncomplicated malaria. Pharmacokinetic (PK) properties in pregnant women are often based on small studies and need to be confirmed and validated in larger pregnant ...Junjie Ding, Richard M. Hoglund, Harry Tagbor, Halidou Tinto, Innocent Valéa, Victor Mwapasa, Linda Kalilani‐Phiri, Jean‐Pierre Van Geertruyden, Michael Nambozi, Modest Mulenga, Sebastian Hachizovu, Raffaella Ravinetto, Umberto D'Alessandro, Joel Tarning +13 moredoaj +1 more sourcePopulation pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria.
, 2012 Pregnant women are particularly vulnerable to malaria. The pharmacokinetic properties of antimalarial drugs are often affected by pregnancy, resulting in lower drug concentrations and a consequently higher risk of treatment failure. The objective of this Phyo, AP, McGready, R, Mcgready, Rose, Hanpithakpong, W, Day, Nicholas, Lindegardh, N, Nosten, Francois, Tarning, J, Rijken, MJ, Day, NP, White, NJ, White, Nicholas, Nosten, F, Tarning, Joel +13 morecore +1 more sourceOpen-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects.
, 2014 Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is ...Sasithon Pukrittayakamee, Lee, Sue, Ashley, EA, Pukrittayakamee, S, Hanpithakpong, W, Thanaporn Wattanakul, Tarning, J, Warunee Hanpithakpong, Day, NP, Salwaluk Panapipat, Panapipat, S, Sue J. Lee, Lee, SJ, Nicholas P. J. Day, Hanboonkunupakarn, B, Podjanee Jittamala, Joel Tarning, Wattanakul, T, Borimas Hanboonkunupakarn, Chotsiri, P, Palang Chotsiri, Nicholas J. White, Day, Nicholas, White, NJ, White, Nicholas, Elizabeth A. Ashley, Jittamala, P +26 morecore +1 more sourceAdverse events recorded within day 0 to day 3 after MDA using dihydroartemisinin-piperaquine.
, 2019 Adverse events recorded within day 0 to day 3 after MDA using dihydroartemisinin-piperaquine.Thuy-Nhien Nguyen (3624017), Georges Snounou (69427), Lilly Keereecharoen (3421451), Panom Phongmany (761350), Nils Kaehler (573077), Gisela Henriques (363295), Nguyen Thi Kim Tuyen (6368573), Nguyen Tuong-Vy (6368561), Thomas J. Peto (3157794), Borimas Hanboonkunupakarn (571549), Vincent Corbel (63075), Nguyen Thanh Tien (2166763), Nicholas J. White (35779), Jeremy Chalk (3157791), Paul N. Newton (132889), Rupam Tripura (731049), Nicholas P. J. Day (35781), Mavuto Mukaka (85985), Cholrawee Promnarate (3157797), Christopher Pell (213076), Lisa J. White (101780), Preyanan Suangkanarat (3421445), Le Thanh Dong (6390587), Khin Maung Lwin (171017), Sue J. Lee (140486), Daniel M. Parker (394729), Kesinee Chotivanich (140505), Francois H. Nosten (5660191), May Myo Thwin (170999), Jordi Landier (197677), Pimnara Peerawaranun (6390605), Guy E. Thwaites (192873), Stephane Proux (17227), Mehul Dhorda (351592), Krittaya Patumrat (3707008), Huynh Hong Quang (6390593), Chan Davoeung (3707017), Benchawan Vihokhern (3421463), Frank Smithuis (261437), Benoit Malleret (3421457), Chea Nguon (161886), Carl Onsjö (6390599), Phaik Yeong Cheah (363605), Podjanee Jittmala (6390602), Julie A. Simpson (242873), Huy Rekol (3511403), Atthanee Jeeyapant (2602648), Pratap Singhasivanon (17235), Bipin Adhikari (573076), Yoel Lubell (88683), Tran Tinh Hien (74675), Xin Hui Chan (4039925), Do Hung Son (6368567), Sasithon Pukrittayakamee (101751), Olivo Miotto (36337), Truong Le Phuc-Nhi (6368564), Mallika Imwong (151642), Laurent Rénia (2935842), Jacher Wiladphaingern (171011), Mayfong Mayxay (132900), Tiengkham Pongvongsa (244713), Koukeo Phommasone (452036), Ricardo Aguas (5656675), Martin P. Grobusch (242391), Arjen M. Dondorp (140509), Ladda Kajeechiwa (2580784), Dao Van Hue (6390590), Rob W. van der Pluijm (6390596), Pham Nguyen Huong-Thu (6368570), Lorenz von Seidlein (45473), Suphak Nosten (2580802), Pasathorn Sirithiranont (3421475), Frank Cobelens (109566) +72 morecore +1 more sourceDihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.
, 2004 BACKGROUND: Southeast Asia has the most resistant malaria parasites in the world, which severely limits treatment options. There is general acceptance that to combat resistance, combinations of antimalarial drugs that include an artemisinin derivative ...Tran, TH, Dolecek, Christiane, Farrar, J, Nguyen, TD, Farrar, Jeremy, Le, HT, Tran, TT, Stepniewska, K, Dong, TH, Pham, PM, Dolecek, C, White, NJ, Nguyen, TT, White, Nicholas +13 morecore +1 more source
